Zim Laboratories Schedules Q3 & 9MFY26 Earnings Conference Call for Feb 13
Zim Laboratories Limited will host its Q3 & 9MFY26 Earnings Conference Call on February 13, 2026, at 10:00 AM IST. The call will include the Chairman, Director (Finance), CFO, and Investor Relations. Participants can pre-register and use provided dial-in numbers.
This is a standard procedural announcement for an upcoming earnings call and does not contain material financial information or strategic changes that would significantly impact the company's stock or operations.
The announcement is a routine intimation of a scheduled conference call for earnings, with no new financial or business performance data provided.
Zim Laboratories Limited has announced that its Q3 and 9MFY26 Earnings Conference Call is scheduled for Friday, February 13, 2026, at 10:00 a.m. IST.
The call will feature key management personnel including Dr. Anwar Siraj Daud, Chairman and Managing Director; Mr. Zulfiquar Kamal, Director (Finance); Mr. Shyam Mohan Patro, Chief Financial Officer; and Mr. Zain Daud, Investor Relations.
Participants are encouraged to pre-register via a provided link to minimize wait times and join using DiamondPass. Dial-in numbers for the conference are 086 3416 8857 and 086 4536 7332. Attendees are advised to dial in 5-10 minutes prior to the scheduled start time.
What to do with a filing like this
Zim Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under concall scheduled. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zim Laboratories Limited. Read the original for the full detail.